What is INO's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.12B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for INO?

P/E (TTM) is n/a and 52-week range is $0.56 to $2.72 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s INO figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for INO?

The company profile lists revenue (TTM) near $283K, net income (TTM) near $-7.11B, EPS (TTM) near $-1.17 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Inovio Pharmaceuticals Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Plymouth Meeting, Pennsylvania, US, 82.3M shares outstanding, ISIN US45773H4092 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Inovio Pharmaceuticals Inc

$INO

Health Care · Biotechnology

IR Run Scenarios

$1.15

+5.50%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. The company is headquartered in Plymouth Meeting, Pennsylvania and currently employs 112 full-time employees. Its proprietary investigational CELLECTRA devices are designed to deliver the plasmids into the body’s cells for optimal effect, without the use of chemical adjuvants, lipid nanoparticles or viral vectors. Its lead candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease caused by HPV-6 and HPV-11. Its DNA medicines in the pipeline include INO-3112 for the Treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma, VGX-3100 for the Treatment of HPV-related Cervical HSIL, VGX-3100 for the Treatment of Anal or Perianal HSIL, INO-5401 for the Treatment of Glioblastoma Multiforme (GBM), and INO-5401 for the Prevention of Cancer for People with BRCA1/2 Mutation.

Employees

112

Website

www.inovio.com/

IPO

1998-12-08

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)